scispace - formally typeset
Search or ask a question
Author

Germán Bou

Bio: Germán Bou is an academic researcher from University of A Coruña. The author has contributed to research in topics: Acinetobacter baumannii & Imipenem. The author has an hindex of 58, co-authored 308 publications receiving 17715 citations. Previous affiliations of Germán Bou include National University of Rosario & Autonomous University of Madrid.


Papers
More filters
Journal ArticleDOI
Daniel J. Klionsky1, Kotb Abdelmohsen2, Akihisa Abe3, Joynal Abedin4  +2519 moreInstitutions (695)
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Abstract: In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. For example, a key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process versus those that measure flux through the autophagy pathway (i.e., the complete process including the amount and rate of cargo sequestered and degraded). In particular, a block in macroautophagy that results in autophagosome accumulation must be differentiated from stimuli that increase autophagic activity, defined as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (in most higher eukaryotes and some protists such as Dictyostelium) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. It is worth emphasizing here that lysosomal digestion is a stage of autophagy and evaluating its competence is a crucial part of the evaluation of autophagic flux, or complete autophagy. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. Along these lines, because of the potential for pleiotropic effects due to blocking autophagy through genetic manipulation, it is imperative to target by gene knockout or RNA interference more than one autophagy-related protein. In addition, some individual Atg proteins, or groups of proteins, are involved in other cellular pathways implying that not all Atg proteins can be used as a specific marker for an autophagic process. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular assays, we hope to encourage technical innovation in the field.

5,187 citations

Journal ArticleDOI
Marina Pollán1, Beatriz Pérez-Gómez1, Roberto Pastor-Barriuso1, Jesús Oteo1, Miguel A. Hernán2, Miguel A. Hernán3, Mayte Pérez-Olmeda1, Jose L Sanmartín, Aurora Fernández-García4, Aurora Fernández-García1, Israel Cruz1, Nerea Fernández de Larrea1, Marta Molina, Francisco Rodríguez-Cabrera1, Mariano Martín, Paloma Merino-Amador4, Jose León Paniagua1, Juan F Muñoz-Montalvo, Faustino Blanco, Raquel Yotti1, Rodrigo Gutiérrez Fernández, Saturnino Mezcua Navarro, Matías Salinero Hernández, Manuel Cuenca-Estrella, Pablo Fernández-Navarro, Ana Avellón, Giovanni Fedele, Jesús Oteo Iglesias, María Teresa Pérez Olmeda, Maria Elena Martinez, Francisco D. Rodríguez-Cabrera1, Susana Padrones Fernández, José Manuel Rumbao Aguirre, José M. Navarro Marí, Begoña Palop Borrás, Ana Belén Pérez Jiménez, Manuel Rodríguez-Iglesias, Ana María Calvo Gascón, María Luz Lou Alcaine, Ignacio Donate Suárez, Oscar Suárez Álvarez, Mercedes Rodríguez Pérez, Margarita Cases Sanchís, Carlos Javier Villafáfila Gomila, Lluis Carbo Saladrigas, Adoración Hurtado Fernández, Antonio Oliver, Elías Castro Feliciano, María Noemí González Quintana, José María Barrasa Fernández, María Araceli Hernández Betancor, Melisa Hernández Febles, Leopoldo Martín Martín, Luis-Mariano López López, Teresa Ugarte Miota, Inés De Benito Población, María Sagrario Celada Pérez, María Natalia Vallés Fernández, Tomás Maté Enríquez, Miguel Villa Arranz, Marta Domínguez-Gil González, Isabel Fernández-Natal, Gregoria Megías Lobón, Juan Luis Muñoz Bellido, Pilar Ciruela, Ariadna Mas i Casals, Maria Doladé Botías, M. Angeles Marcos Maeso, Dúnia Pérez del Campo, Antonio Félix de Castro, Ramón Limón Ramírez, Maria Francisca Elías Retamosa, Manuela Rubio González, María Sinda Blanco Lobeiras, Alberto Fuentes Losada, Antonio Aguilera, Germán Bou, Yolanda Caro, Noemí Marauri, Luis Miguel Soria Blanco, Isabel González, Montserrat Hernández Pascual, Roberto Alonso Fernández, Natalia Cabrera Castro, Aurora Tomás Lizcano, Cristóbal Ramírez Almagro, M. Hernández, Nieves Ascunce Elizaga, María Ederra Sanz, Carmen Ezpeleta Baquedano, Ana Bustinduy Bascaran, Susana Iglesias Tamayo, Luis Elorduy Otazua, Rebeca Benarroch Benarroch, Jesús Lopera Flores, Antonia Vázquez de la Villa 
TL;DR: In this paper, a nationwide population-based study aims to estimate the seroprevalence of SARS-CoV-2 infection in Spain at national and regional level.

1,435 citations

Journal ArticleDOI
TL;DR: This review considers how bacterial virulence and fitness are affected by antibiotic resistance and also how the relationship between virulent and resistance is affected by different genetic mechanisms and by the most prevalent global responses.
Abstract: Hosts and bacteria have coevolved over millions of years, during which pathogenic bacteria have modified their virulence mechanisms to adapt to host defense systems. Although the spread of pathogens has been hindered by the discovery and widespread use of antimicrobial agents, antimicrobial resistance has increased globally. The emergence of resistant bacteria has accelerated in recent years, mainly as a result of increased selective pressure. However, although antimicrobial resistance and bacterial virulence have developed on different timescales, they share some common characteristics. This review considers how bacterial virulence and fitness are affected by antibiotic resistance and also how the relationship between virulence and resistance is affected by different genetic mechanisms (e.g., coselection and compensatory mutations) and by the most prevalent global responses. The interplay between these factors and the associated biological costs depend on four main factors: the bacterial species involved, virulence and resistance mechanisms, the ecological niche, and the host. The development of new strategies involving new antimicrobials or nonantimicrobial compounds and of novel diagnostic methods that focus on high-risk clones and rapid tests to detect virulence markers may help to resolve the increasing problem of the association between virulence and resistance, which is becoming more beneficial for pathogenic bacteria.

739 citations

Journal ArticleDOI
Bernard Dujon1, Despina Alexandraki2, Bruno André3, W. Ansorge, Victoriano Baladrón4, Juan P. G. Ballesta5, Andrea Banrevi, P. A. Bolle, Monique Bolotin-Fukuhara6, Peter Bossier7, Germán Bou5, J. Boyer1, M. J. Buitrago4, Geneviève Chéret, Laurence Colleaux1, B. Dalgnan-Fornier6, F. del Rey4, Caroline Dion, H. Domdey, A. Düsterhöft, S. Düsterhus8, K. D. Entian8, Holger Erfle, Pedro F. Esteban4, Heidi Feldmann9, L. Fernandes7, G. M. Fobo, C. Fritz, Hiroshi Fukuhara, C. Gabel, L. Gaillon1, J. M. Carcia-Cantalejo5, José J. García-Ramírez4, Manda E. Gent10, Marjan Ghazvini1, Marjan Ghazvini11, André Goffeau12, A. Gonzaléz4, Dietmar Grothues, Paulo Guerreiro7, Johannes H. Hegemann, N. Hewitt, François Hilger, Cornelis P. Hollenberg, O. Horaitis13, O. Horaitis2, Keith J. Indge10, Alain Jacquier1, C. M. James10, J. C. Jauniaux3, J. C. Jauniaux14, A. Jimenez5, H. Keuchel, L. Kirchrath, K. Kleine, Peter Kötter8, Pierre Legrain1, S. Liebl, Edward J. Louis15, A. Maia e Silva7, Christian Marck, A.-L. Monnier1, D. Mostl, Sylke Müller, B. Obermaier, Stephen G. Oliver10, C. Pallier6, Steve Pascolo1, Steve Pascolo11, Friedhelm Pfeiffer, Peter Philippsen, Rudi J. Planta16, Fritz M. Pohl17, Thomas Pohl, Regina Pohlmann, Daniel Portetelle, Bénédicte Purnelle12, V. Puzos6, M. Ramezani Rad, S. W. Rasmussen18, Miguel Remacha5, José L. Revuelta4, Guy-Franck Richard1, Martin Rieger, Claudina Rodrigues-Pousada7, Matthias Rose8, Thomas Rupp, Maria A. Santos4, Christian Schwager, Christoph Wilhelm Sensen, J. Skala12, J. Skala19, Helena Soares7, Frédéric Sor, J. Stegemann, Hervé Tettelin12, Alain R. Thierry1, M. Tzermia2, L. A. Urrestarazu3, L Van Dyck12, J. C. van Vliet-Reedijk16, Michèle Valens6, M. Vandenbo, C. Vilela7, Stephan Vissers3, D. von Wettstein18, H. Voss, Stefan Wiemann, G. Xu, Jürgen Zimmermann, M. Haasemann6, I. Becker, Hans-Werner Mewes 
02 Jun 1994-Nature
TL;DR: The complete DNA sequence of the yeast Saccharomyces cerevisiae chromosome XI has been determined, and the 666,448-base-pair sequence has revealed general chromosome patterns.
Abstract: The complete DNA sequence of the yeast Saccharomyces cerevisiae chromosome XI has been determined. In addition to a compact arrangement of potential protein coding sequences, the 666,448-base-pair sequence has revealed general chromosome patterns; in particular, alternating regional variations in average base composition correlate with variations in local gene density along the chromosome. Significant discrepancies with the previously published genetic map demonstrate the need for using independent physical mapping criteria.

383 citations

Journal ArticleDOI
Belén Gutiérrez-Gutiérrez1, Elena Salamanca1, Marina de Cueto1, Po-Ren Hsueh2, Pierluigi Viale, José Ramón Paño-Pardo3, Mario Venditti4, Mario Tumbarello5, George L. Daikos6, Rafael Cantón, Yohei Doi7, Felipe Francisco Tuon8, Ilias Karaiskos, Elena Pérez-Nadales9, Mitchell J. Schwaber10, Mitchell J. Schwaber11, Özlem Kurt Azap12, Maria Souli, Emmanuel Roilides, Spyros Pournaras6, Murat Akova13, Federico Perez14, Joaquín Bermejo, Antonio Oliver, Manel Almela, Warren Lowman15, Benito Almirante, Robert A. Bonomo16, Robert A. Bonomo14, Yehuda Carmeli10, Yehuda Carmeli11, David L. Paterson17, Álvaro Pascual18, Álvaro Pascual1, Jesús Rodríguez-Baño1, Jesús Rodríguez-Baño18, M.D. del Toro, Jorge Galvez, Marco Falcone, Alessandro Russo, Helen Giamarellou, Enrico Maria Trecarichi, Angela Raffaella Losito, E. García-Vázquez, Alicia Hernandez, J. Gómez, Germán Bou, Elias Iosifidis, N. Prim, Ferran Navarro, Beatriz Mirelis, Anna Skiada, Julia Origüen, R. San Juan, Mario Fernández-Ruiz, Nieves Larrosa, Mireia Puig-Asensio, José Miguel Cisneros, José Molina, V. González, V. Rucci, E. Ruiz de Gopegui, C. I. Marinescu, Luis Martínez-Martínez, M.C. Fariñas, M. E. Cano, Mónica Gozalo, Marta Mora-Rillo, C. Navarro-San Francisco, Carmen Peña, Silvia Gómez-Zorrilla, Fe Tubau, Athanassios Tsakris, O. Zarkotou, Anastasia Antoniadou, Garyphallia Poulakou, Johann D. D. Pitout, Deepali Virmani, J. Torre-Cisneros, Julia Guzmán-Puche, Ö. Helvaci, A. O. Sahin, Vicente Pintado, Patricia Cordero Ruiz, Michele Bartoletti, Maddalena Giannella, Evelina Tacconelli, F. Riemenschneider, Esther Calbo, Cristina Badia, M. Xercavins, Oriol Gasch, D. Fontanals, E. Jové 
TL;DR: Patients with BSIs due to CPE should receive active therapy as soon as they are diagnosed, and monotherapy should be considered for those in the low-mortality-score stratum.
Abstract: Summary Background The best available treatment against carbapenemase-producing Enterobacteriaceae (CPE) is unknown. The objective of this study was to investigate the effect of appropriate therapy and of appropriate combination therapy on mortality of patients with bloodstream infections (BSIs) due to CPE. Methods In this retrospective cohort study, we included patients with clinically significant monomicrobial BSIs due to CPE from the INCREMENT cohort, recruited from 26 tertiary hospitals in ten countries. Exclusion criteria were missing key data, death sooner than 24 h after the index date, therapy with an active antibiotic for at least 2 days when blood cultures were taken, and subsequent episodes in the same patient. We compared 30 day all-cause mortality between patients receiving appropriate (including an active drug against the blood isolate and started in the first 5 days after infection) or inappropriate therapy, and for patients receiving appropriate therapy, between those receiving active monotherapy (only one active drug) or combination therapy (more than one). We used a propensity score for receiving combination therapy and a validated mortality score (INCREMENT-CPE mortality score) to control for confounders in Cox regression analyses. We stratified analyses of combination therapy according to INCREMENT-CPE mortality score (0–7 [low mortality score] vs 8–15 [high mortality score]). INCREMENT is registered with ClinicalTrials.gov, number NCT01764490. Findings Between Jan 1, 2004, and Dec 31, 2013, 480 patients with BSIs due to CPE were enrolled in the INCREMENT cohort, of whom we included 437 (91%) in this study. 343 (78%) patients received appropriate therapy compared with 94 (22%) who received inappropriate therapy. The most frequent organism was Klebsiella pneumoniae (375 [86%] of 437; 291 [85%] of 343 patients receiving appropriate therapy vs 84 [89%] of 94 receiving inappropriate therapy) and the most frequent carbapenemase was K pneumoniae carbapenemase (329 [75%]; 253 [74%] vs 76 [81%]). Appropriate therapy was associated with lower mortality than was inappropriate therapy (132 [38·5%] of 343 patients died vs 57 [60·6%] of 94; absolute difference 22·1% [95% CI 11·0–33·3]; adjusted hazard ratio [HR] 0·45 [95% CI 0·33–0·62]; p vs 85 [41%] of 208; adjusted HR 1·63 [95% CI 0·67–3·91]; p=0·28). However, combination therapy was associated with lower mortality than was monotherapy in the high-mortality-score stratum (30 [48%] of 63 vs 64 [62%] of 103; adjusted HR 0·56 [0·34–0·91]; p=0·02), but not in the low-mortality-score stratum (17 [24%] of 72 vs 21 [20%] of 105; adjusted odds ratio 1·21 [0·56–2·56]; p=0·62). Interpretation Appropriate therapy was associated with a protective effect on mortality among patients with BSIs due to CPE. Combination therapy was associated with improved survival only in patients with a high mortality score. Patients with BSIs due to CPE should receive active therapy as soon as they are diagnosed, and monotherapy should be considered for those in the low-mortality-score stratum. Funding Spanish Network for Research in Infectious Diseases, European Development Regional Fund, Instituto de Salud Carlos III, and Innovative Medicines Initiative.

380 citations


Cited by
More filters
01 Jun 2012
TL;DR: SPAdes as mentioned in this paper is a new assembler for both single-cell and standard (multicell) assembly, and demonstrate that it improves on the recently released E+V-SC assembler and on popular assemblers Velvet and SoapDeNovo (for multicell data).
Abstract: The lion's share of bacteria in various environments cannot be cloned in the laboratory and thus cannot be sequenced using existing technologies. A major goal of single-cell genomics is to complement gene-centric metagenomic data with whole-genome assemblies of uncultivated organisms. Assembly of single-cell data is challenging because of highly non-uniform read coverage as well as elevated levels of sequencing errors and chimeric reads. We describe SPAdes, a new assembler for both single-cell and standard (multicell) assembly, and demonstrate that it improves on the recently released E+V-SC assembler (specialized for single-cell data) and on popular assemblers Velvet and SoapDeNovo (for multicell data). SPAdes generates single-cell assemblies, providing information about genomes of uncultivatable bacteria that vastly exceeds what may be obtained via traditional metagenomics studies. SPAdes is available online ( http://bioinf.spbau.ru/spades ). It is distributed as open source software.

10,124 citations

Journal ArticleDOI
TL;DR: A comprehensive overview of the current understanding of the physiological roles of EVs is provided, drawing on the unique EV expertise of academia-based scientists, clinicians and industry based in 27 European countries, the United States and Australia.
Abstract: In the past decade, extracellular vesicles (EVs) have been recognized as potent vehicles of intercellular communication, both in prokaryotes and eukaryotes. This is due to their capacity to transfer proteins, lipids and nucleic acids, thereby influencing various physiological and pathological functions of both recipient and parent cells. While intensive investigation has targeted the role of EVs in different pathological processes, for example, in cancer and autoimmune diseases, the EV-mediated maintenance of homeostasis and the regulation of physiological functions have remained less explored. Here, we provide a comprehensive overview of the current understanding of the physiological roles of EVs, which has been written by crowd-sourcing, drawing on the unique EV expertise of academia-based scientists, clinicians and industry based in 27 European countries, the United States and Australia. This review is intended to be of relevance to both researchers already working on EV biology and to newcomers who will encounter this universal cell biological system. Therefore, here we address the molecular contents and functions of EVs in various tissues and body fluids from cell systems to organs. We also review the physiological mechanisms of EVs in bacteria, lower eukaryotes and plants to highlight the functional uniformity of this emerging communication system.

3,690 citations

Journal ArticleDOI
TL;DR: This document summarizes current knowledge about three-dimensional AIDS, congenital heart disease, cardiac device-related infective endocarditis, and cardiac implantable electronic device in the context of acquired immune deficiency syndrome.
Abstract: 3D : three-dimensional AIDS : acquired immune deficiency syndrome b.i.d. : bis in die (twice daily) BCNIE : blood culture-negative infective endocarditis CDRIE : cardiac device-related infective endocarditis CHD : congenital heart disease CIED : cardiac implantable electronic device

3,510 citations

Journal ArticleDOI
TL;DR: Extended-spectrum β-lactamases represent an impressive example of the ability of gram-negative bacteria to develop new antibiotic resistance mechanisms in the face of the introduction of new antimicrobial agents.
Abstract: Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases which share the ability to hydrolyze third-generation cephalosporins and aztreonam yet are inhibited by clavulanic acid. Typically, they derive from genes for TEM-1, TEM-2, or SHV-1 by mutations that alter the amino acid configuration around the active site of these β-lactamases. This extends the spectrum of β-lactam antibiotics susceptible to hydrolysis by these enzymes. An increasing number of ESBLs not of TEM or SHV lineage have recently been described. The presence of ESBLs carries tremendous clinical significance. The ESBLs are frequently plasmid encoded. Plasmids responsible for ESBL production frequently carry genes encoding resistance to other drug classes (for example, aminoglycosides). Therefore, antibiotic options in the treatment of ESBL-producing organisms are extremely limited. Carbapenems are the treatment of choice for serious infections due to ESBL-producing organisms, yet carbapenem-resistant isolates have recently been reported. ESBL-producing organisms may appear susceptible to some extended-spectrum cephalosporins. However, treatment with such antibiotics has been associated with high failure rates. There is substantial debate as to the optimal method to prevent this occurrence. It has been proposed that cephalosporin breakpoints for the Enterobacteriaceae should be altered so that the need for ESBL detection would be obviated. At present, however, organizations such as the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) provide guidelines for the detection of ESBLs in klebsiellae and Escherichia coli. In common to all ESBL detection methods is the general principle that the activity of extended-spectrum cephalosporins against ESBL-producing organisms will be enhanced by the presence of clavulanic acid. ESBLs represent an impressive example of the ability of gram-negative bacteria to develop new antibiotic resistance mechanisms in the face of the introduction of new antimicrobial agents.

3,308 citations

Journal ArticleDOI
Lorenzo Galluzzi1, Lorenzo Galluzzi2, Ilio Vitale3, Stuart A. Aaronson4  +183 moreInstitutions (111)
TL;DR: The Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives.
Abstract: Over the past decade, the Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for the definition and interpretation of cell death from morphological, biochemical, and functional perspectives. Since the field continues to expand and novel mechanisms that orchestrate multiple cell death pathways are unveiled, we propose an updated classification of cell death subroutines focusing on mechanistic and essential (as opposed to correlative and dispensable) aspects of the process. As we provide molecularly oriented definitions of terms including intrinsic apoptosis, extrinsic apoptosis, mitochondrial permeability transition (MPT)-driven necrosis, necroptosis, ferroptosis, pyroptosis, parthanatos, entotic cell death, NETotic cell death, lysosome-dependent cell death, autophagy-dependent cell death, immunogenic cell death, cellular senescence, and mitotic catastrophe, we discuss the utility of neologisms that refer to highly specialized instances of these processes. The mission of the NCCD is to provide a widely accepted nomenclature on cell death in support of the continued development of the field.

3,301 citations